Clinical trial
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
NCT00446095 · Rigel Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00446095 |
|---|---|
| Title | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma |
| Official title | A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma |
| Lead sponsor | Rigel Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | fostamatinib |
| Enrollment | 81 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Mar 12, 2007 |
| Last update posted | Sep 19, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: